title: Thermal ablation of the small renal mass: case selection using the R.E.N.A.L.-Nephrometry Score.
abstract: OBJECTIVE
  Treatment decision-making for localized renal lesions remains overly subjective. While the AUA Guidelines list thermal ablation (TA) as a treatment option for the clinical T1 renal mass, few data exist regarding the relationship between TA and tumor complexity. The R.E.N.A.L.-Nephrometry Scoring System (NS) was introduced to objectify salient renal mass anatomy and standardize academic reporting. Here we correlate the salient anatomical attributes of renal masses undergoing TA with technical and oncologic outcomes.
  
  
  METHODS
  We queried our prospectively maintained kidney cancer database of 2,312 patients and identified 39 patients who underwent TA with available nephrometry scores. Patient clinical, technical, functional, and oncologic characteristics were reviewed.
  
  
  RESULTS
  Median patient age, serum creatinine, estimated glomerular filtration rate, and Charlson Comorbidity Index were 71 (range = 57-86) years, 1.37 (range = 0.7-3.5) mg/dl, 57.1 (range = 23.3-93.8) ml/min, and 2 (range = 0-5), respectively. Median Nephrometry Score for patients undergoing tumor ablation was 6 (4-10). Low (NS = 4-6), moderate (NS = 7-9), and high (NS = 10-12) complexity tumors were identified in 20 (51.3%), 17 (43.6%), and 2 (5.1%) patients. Six (15%) patients experienced a tumor recurrence. Of those with a recurrence, 5/6 (83.3%) had moderate complexity tumors with the remaining tumor being low complexity. Minor and major Clavien complications occurred in 4 (10%) and 1 (3%) patients, all of whom had moderate complexity tumors.
  
  
  CONCLUSIONS
  At our institution, 95% of tumors undergoing TA were anatomically low or moderate complexity lesions as measured by the R.E.N.A.L.-Nephrometry Scoring System. Nephrometry may help predict disease recurrence and peri-procedural complications, yet multi-institutional analysis is needed to further validate these findings.
authors.affiliation: Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
authors.forename: Jose
authors.initials: J
authors.lastname: Reyes
authors.forename: Daniel
authors.initials: D
authors.lastname: Canter
authors.forename: Samuel
authors.initials: S
authors.lastname: Putnam
authors.forename: Jay
authors.initials: J
authors.lastname: Simhan
authors.forename: Marc C
authors.initials: MC
authors.lastname: Smaldone
authors.forename: Alexander
authors.initials: A
authors.lastname: Kutikov
authors.forename: Rosalia
authors.initials: R
authors.lastname: Viterbo
authors.forename: David Y T
authors.initials: DY
authors.lastname: Chen
authors.forename: Robert G
authors.initials: RG
authors.lastname: Uzzo
mesh_terms: D055011:Ablation Techniques / Q000379:methods*; D000368:Aged; D000369:Aged, 80 and over; D003404:Creatinine / Q000097:blood; D016208:Databases, Factual / Q000706:statistics & numerical data; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000473:pathology* / Q000601:surgery*; D007680:Kidney Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D011446:Prospective Studies; D015203:Reproducibility of Results
chemical_list: D003404:Creatinine